Trial Profile
A phase II trial of docetaxel plus carboplatin plus bevacizumab as neoadjuvant therapy for triple negative breast cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jan 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Docetaxel (Primary)
- Indications Advanced breast cancer; Early breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 20 Jan 2016 New trial record